FDA hands Arbutus clinical hold on IND for hepatitis PD-L1
The FDA placed a clinical hold on Arbutus Biopharma’s experimental PD-L1 that is designed to treat patients with chronic hepatitis B virus.
The biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
